Indolocarbazoles. Potent and selective inhibitors of platelet-derived growth factor receptor autophosphorylation

Biochemical Pharmacology

Volumn 55, Issue 3, 1998, Pages 261-271

  Spacey, Graham D ^a   Uings, Iain J ^a   Slater, Martin ^a   Hirst, Stuart ^b   Bonser, Robert W ^a,c  

^a WELLCOME RESEARCH LABORATORIES   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

A10 cells; Human smooth muscle cells; Platelet derived growth factor; Receptor autophosphorylation; Tyrosine kinase

Indexed keywords

3,9 DIMETHOXYINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7 DIONE; 3744W; INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN SERINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; BIOASSAY; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARBAZOLES; CELLS, CULTURED; DNA REPLICATION; ENZYME INHIBITORS; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PHTHALIMIDES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN BINDING; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECOMBINANT PROTEINS; TRACHEA; TUMOR CELLS, CULTURED;

EID: 0032007528     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00460-7     Document Type: Article

References (64)

1. Pledger WJ, Stiles CD, Antionaides HN, Scher CD. Induction of DNA synthesis in BALB/c3T3 cells by serum components Reevaluation of the commitment process . Proc Natl Acad Sci USA. 74:1977;4481-4485.
2. Raines EW, Bowen-Pope DF, and Ross R, Platelet-derived growth factor. In: Handbook of Experimental Pharmacology Peptide Growth Factors and Their Receptors. Part 1 (Eds. Sporn MB and Roberts AB), pp. 173-262. Springer-Verlag, Heidelberg, 1986.
3. Heldin C-H, Westermark B. Platelet-derived growth factor mechanism of action and possible in vivo function . Cell Regulation. 1:1990;555-566.
4. Soma Y, Takehara K, Ishibashi Y. Alteration of the chemotactic response of human skin fibroblasts to PDGF by growth factors. Exp Cell Res. 212:1994;274-277.
5. Bomfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-1 and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signalling pathways that are distinct from those of proliferation. J Clin Invest. 93:1994;1266-1274.
6. Barnes JL, Hevey KA. Glomerular mesangial cell migration in response to platelet-derived growth factor. Lab Invest. 62:1990;379-382.
7. Westermark B, Heldin C-H. Platelet-derived growth factor structure function and implications in normal and malignant cell growth . Acta Oncol. 32:1993;101-105.
8. Forsberg K, Valyi-Nagy I, Heldin C-H, Herlyn M, Westermark B. Platelet-derived growth factor (PDGF) in oncogenesis Development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB . Proc Natl Acad Sci USA. 90:1993;393-397.
9. Gesualdo L, Di Paolo S, Milani S, Pinzani M, Grappone C, Ranieri E, Pannarale G, Schena FP. Expression of platelet-derived growth factor receptors in normal and diseased human kidney. J Clin Invest. 94:1994;50-58.
10. Abboud HE. Role of platelet-derived growth factor in renal injury. Annu Rev Physiol. 57:1995;297-309.
11. Halayko AJ, Stephens NL. Potential role for phenotypic modulation of bronchial smooth muscle cells in chronic asthma. Can J Physiol Pharmacol. 72:1994;1448-1457.
12. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 57:1995;791-804.
13. Molloy CJ. Novel signal transduction targets in cardiovascular disease Role of platelet-derived growth factor in vascular smooth muscle cell proliferation . Drug Dev Res. 29:1993;148-157.
14. Escobedo JA, Williams LT. A PDGF receptor domain essential for mitogenesis but not for many other responses to PDGF. Nature. 335:1988;85-87.
15. Westermark B, Siegbahn A, Heldin C-H, Claesson-Welsh L. B-type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand induced activation of the receptor protein-tyrosine kinase. Proc Natl Acad Sci USA. 87:1990;128-132.
16. Bilder GE, Krawiec JA, Mcvety K, Gazit A, Gilon C, Lyall R, Zilberstein A, Levitzki A, Perrone MH, Schreiber AB. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am J Physiol. 29:1991;C721-C730.
17. Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin C-H, Waltenberger J, Bohmer F-D, Levitzki A. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 54:1994;6106-6114.
18. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, Lydon NB. Selective inhibiton of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA. 92:1995;2558-2562.
19. Buchdunger E, Regenass U. Differential inhibition of the epidermal growth factor-platelet-derived growth factor- and protein kinase C- mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res. 52:1992;5353-5358.
20. Bilder GE, Kasiewski CJ, Walczak EM, Perrone MH. PDGF-receptor protein tyrosine kinase activity in carotid artery is enhanced by injury and inhibited in vivo by tyrphostin RG 13291. Drug Dev Res. 29:1993;158-166.
21. Maguire MP, Sheets KR, Mcvety K, Spada A, Zilberstein A. A new series of PDGF receptor tyrosine kinase inhibitors 3-substituted quinoline derivatives . J Med Chem. 37:1994;2129-2137.
22. Meyer T, Regenass Fabbro D, Alter E, Rosel J, Muller M, Caravatti G, Matter A. A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro antiproliferative as well as in vivo anti-tumour activity. Int J Cancer. 43:1989;851-856.
23. Spacey GD, Bonser RW, Randall RW, Garland LG. Selectivity of protein kinase inhibitors in human intact platelets. Cell Signal. 2:1990;329-338.
24. Bergman J, Pelcman B. Synthesis of indolo[2,3-a]pyrrolo-[3,4-c]carbazoles by double Fischer indolizations. J Org Chem. 54:1989;824-828.
25. Fager G, Hansson GK, Ottosson P, Dahllof N, Bondjers G. Human arterial smooth muscle cells in culture Effects of platelet-derived growth factor and heparin on growth in vitro . Exp Cell Res. 176:1988;319-335.
26. Hirst SJ, Barnes PJ, Twort CHC. Quantifying proliferation of cultured human and rabbit airway smooth muscle in response to serum and platelet-derived growth factor. Am J Resp Cell Mol Biol. 7:1992;574-581.
27. Peakman TC, Reynolds CH, Willson MG, Moore JD, Spence P, Sydenham M, Linstead DJ, Gewert DR, Page MJ. Expression of the mouse c-abl type IV proto-oncogene product in the insect cell baculovirus system. Biochim Biophys Acta. 1138:1992;68-74.
28. Seifert RA, Hart CE, Phillips PE, Forstrom JW, Ross R, Murray MJ, Bowen-Pope DF. Two different subunits associate to create isoform-specific platelet-derived growth factor receptors. J Biol Chem. 264:1989;8771-8778.
29. Reynolds CH, Willson MG, Groffen J, Heisterkamp N, Peakman TC, Page MJ. Comparison of baculovirus-expressed c-abl and BCR-abl protein tyrosine kinases. Biochim Biophys Acta. 1181:1993;122-130.
30. King IC, Feng M, Catino JJ. High throughput assay for inhibitors of the epidermal growth factor receptor-associated tyrosine kinase. Life Sci. 53:1993;1465-1472.
31. Chang G, El-Gendy K, Abdel-Ghany M, Clark R, McCormick F, Racker E. Isolation of highly purified and stable preparations of c-src and v-src kinase. Cell Physiol Biochem. 1:1991;24-30.
32. Lydon NB, Gay B, Mett H, Murray B, Liebetanz J, Gutzwiller A, Pwinica-Worms H, Roberts TM, Mcglynn E. Purification and biochemical characterisation of non-myristoylated recombinant pp60-src kinase. Biochem J. 287:1992;985-993.
33. Bonser RW, Thompson NT, Hodson HF, Beams RM, Garland LG. Evidence that a second stereochemical centre in diacylglycerols defines interaction at the receptor site on protein kinase C. FEBS Lett. 234:1988;341-344.
34. Roskoski R. Assays of protein kinases. Meth Enzymol. 99:1983;3-6.
35. Fauser AA, Messner HA. Granuloerythropoietic colonies in human bone marrow peripheral blood and cord blood. Blood. 52:1978;1243-1248.
36. Testa N, Molineux G. Haemopoiesis A Practical Approach . 1992;Oxford IRL.
37. Ohmi K, Yamashita S, Nonomura Y. Effects of K252a, a protein kinase inhibitor, on the proliferation of vascular smooth muscle cells. Biochem Biophy Res Commun. 173:1990;976-981.
38. Antionaides HN, Bravo MA, Avila RE, Galanopoulos T, Neville-Golden J, Maxwell M, Selman M. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest. 86:1990;1055-1064.
39. Burt AD. Cellular and molecular aspects of hepatic fibrosis. J Pathol. 170:1993;105-114.
40. Gressner AM. Hepatic fibrogenesis the puzzle of interacting cells fibrogenic cytokines regulatory loops and extracellular matrix molecules . Z Gastroenterol. 30:1992;5-16.
41. Rubin K, Hansson GK, Ronnstrand L, Claesson-Welsh L, Fellstrom B, Tingstrom A, Larson E, Klareskog L, Heldin C-H, Terracio L. Induction of B-type receptors for platelet-derived growth factor in vascular inflammation Possible implications for development of vascular proliferative lesions . Lancet. 1:1988;1353-1356.
42. Barrett TB, Benditt EP. sis (platelet-derived growth factor B chain) gene transcript levels are elevated in human atherosclerotic lesions compared to normal artery. Proc Natl Acad Sci USA. 84:1987;1099-1103.
43. Wilcox JN, Smith KM, Williams LT, Schwartz SM, Gordon D. Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest. 82:1988;1134-1143.
44. Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, Ross R. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med. 175:1992;1413-1416.
45. Ferns GA, Raines EW, Sprugel KH, Montani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 253:1991;1129-1132.
46. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin C-H, Westermark B, Nister M. Platelet-derived growth factor and its receptors in human glioma tissue expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops . Cancer Res. 52:1992;3213-3219.
47. Strawn LM, Mann E, Elliger SS, Chu L, Germain LL, Niederfellner G, Ullrich A, Shawver LK. Inhibition of glioma cell growth by a truncated platelet-derived growth factor-β receptor. J Biol Chem. 269:1994;21215-21222.
48. Guha A. Platelet-derived growth factor A general review with emphasis on astrocytomas . Pediatr Neurosurg. 17:1991;14-20.
49. Shamah SM, Stiles CD, Guha A. Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol. 13:1993;7203-7212.
50. Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME. Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res. 51:1991;4978-4985.
51. Vignaud J-M, Marie B, Klein N, Plenat F, Pech M, Borrelly J, Martinet N, Duprez A, Martinet Y. The Role of platelet-derived growth factor production by tumour-associated macrophages in tumour stroma formation in lung cancer. Cancer Res. 54:1994;5455-5463.
52. Safi A, Sadmi M, Martinet N, Menard O, Vaillant P, Gallati H, Hosang M, Martinet Y. Presence of elevated levels of platelet-derived growth factor in lung adenocarcinoma pleural effusions. Chest. 102:1992;204-207.
53. Chaudhry A, Papanicolaou V, Oberg K, Heldin C-H, Funa K. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumours of the digestive system. Cancer Res. 52:1992;1006-1012.
54. Tsuda T, Yoshida K, Tsujino T, Nakayama H, Kajiyama G, Tahara E. Coexpression of platelet-derived growth factor (PDGF) A-chain and PDGF receptor genes in human gastric carcinomas. Jpn J Cancer Res. 80:1989;813-817.
55. Plate KH, Breier G, Farrell CL, Risau W. Platelet-derived growth factor receptor-β is induced during tumour development and upregulated during tumour progression in endothelial cells in human gliomas. Lab Invest. 67:1992;529-534.
56. Lindmark G, Sundberg C, Glimelius B, Pahlman L, Rubin K, Gerdin B. Stromal expression of platelet-derived growth factor β-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab Invest. 69:1993;682-689.
57. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF β-receptors. J Cell Biol. 125:1994;917-928.
58. Kelly JD, Haldeman BA, Grant FJ, Murray MJ, Seifert RA, Bowen-Pope DF, Cooper JA, Kazlauskas A. Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation. JBC. 266:1991;8987-8992.
59. Schlessinger J, Ullrich A. Growth factor signalling by receptor tyrosine kinases. Biochemistry. 27:1992;3119-3123.
60. Levitzki A, Gazit A. Tyrosine kinase inhibition an approach to drug development . Science. 267:1995;1782-1788.
61. Banai S, Fishbein I, Moscovitz D, Levitzki A, Gazit A, Gertz SD, Perez L and Golomb G, Site-specific controlled-release of a tyrphostin compound inhibits restenosis in the rat carotid model. In: IBC 2nd International Conference on Restenosis October 26-27th 1995, Washington DC, 1995.
62. Yoneda T, Lyall R, Alsina M, Persons P, Spada A, Levitzki A, Zilberstein A, Mundy G. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res. 51:1991;4430-4435.
63. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F. Staurosporine, a potent inhibitor of phospholipid/Ca dependent protein kinase. Biochem Biophys Res Commun. 135:1986;397-402.
64. Nakano H, Kobayashi E, Takahashi I, Tamaoki T, Kuzuu Y, Iba H. Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60. J Antibiot Tokyo. 40:1987;706-708.